Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer | Zendy

D. Ross Camidge | Zendy; Erin L. Schenk | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer

Author(s) -

D. Ross Camidge,

Erin L. Schenk

Publication year - 2020

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2020.09.052

Subject(s) - immunotherapy , lung cancer , cancer , oncology , chemotherapy , targeted therapy , disease , biology , precision medicine , cancer immunotherapy , medicine , cancer research , immunology , pathology

PD1/PD-L1-directed immunotherapy, alone or in combination with chemotherapy, dominates the initial treatment of metastatic non-small cell lung cancer. However, our ability to predict who will benefit from these approaches is limited. In this issue of Cell, Nabet et al. report a novel, blood-based methodology to more accurately predict durable disease control with immunotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research